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ABSTRACT
Background: Glucagonomas are very rare neuroendocrine tumors of pancreatic endocrine islets alpha cells and they 
produced excessive amount of glucagon hormone. Necrolytic migratory erythema (NME) is a rare dermatosis that char-
acterized by erosive, ulcerative and crusted lesions in different sites of the skin and the common cause of this situation 
related to glucagon secreted tumors. NME can occur commonly in man but some rare and recent reports available the oc-
currence of this situation in pet animals especially dogs. Both gross and histological findings in both human and animals 
are similar. This paper reports a NME case with glucagonoma and diabetes mellitus (DM) by clinical, histopathological 
and immunohistochemical examinations.
Case: A 12-year-old, cat presented with complaints of skin lesions in neck region, hyperglycemia, weight loss and history 
of anorexia during the 2 months. Biochemical analysis results revealed high glucose, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), alkaline phosphatase (ALP) and creatinine levels but decreased blood urea nitrogen 
(BUN), total protein and potassium levels. After 2 weeks of anti-diabetic drug treatment, the blood glucose level became 
normal and skin lesions ameliorated but anorexia and weight loss continued. The cat exhibited general weakness and 
pain in abdominal area. Although the clinical sings ameliorated and skin lesions and serum biochemical findings returned 
the relatively normal levels compared the admission, the cat died after 2 weeks of treatment and necropsy performed. At 
necropsy, marked cachexia, loss of skin elasticity and decreased skin thickness were observed. During the examination of 
abdominal cavity of the cat, there was a mass 0.5x0.5 cm in diameter, hard and grayish color was diagnosed at the pan-
creas. In addition, numerous whitish foci were also present the pancreatic tissue. Additionally, enlargement and paleness 
were noticed at the liver. Hemorrhages were observed at the liver, stomach and gut. Histopathologically pancreatic mass 
composed of polygonal neoplastic cells supported by thin, fibrovascular stroma characteristic for neuroendocrine tumor. 
But type of the cells undistinguished by histopathology for that reason immunohistochemistry performed for to evaluated 
insulin and glucagon secreting cells. Immunohistochemical examination revealed that only small number of insulin secreting 
but numerous glucagon secreting cells in the tumoral tissue and the tumor diagnosed as glucagonoma. Marked decrease 
were also noticed in insulin secretin cells in pancreas and together with high serum glucose levels diabetes mellitus (DM) 
also diagnosed to the cat. Histopathological examination of the skin revealed that decreased skin thickness, alopecia, slight 
inflammatory reaction and necrosis of the spinous layer.
Discussion: Glucagonomas are rare tumors of pancreas even in human, and the incidence of this tumor is very rare in cat. 
They are usually silent tumors and they generally caused by paraneoplastic phenomena than primary clinical symptoms. 
The most prominent features of the “glucagonoma syndrome” are NME and DM. In human NME is commonly diagnosed 
in patient with glucagonoma syndrome.  Very rare NME reports available in cats and dogs. The present cat had obvious 
clinical symptoms and typical skin lesions for NME. This report includes the very characteristic case of NME in a cat due 
to glucagonoma and DM, closely resembling the glucagonoma syndrome occurred in humans. Possible cause of the liver 
damage was also related the DM characterized high serum glucose level. We thought that liver lesions were also supported 
the occurrence of characteristic skin lesions.
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INTRODUCTION
Glucagonomas are very rare neuroendocrine 
tumors of endocrine part of pancreas. They may present 
together with paraneoplastic phenomena known as “glu-
cagonoma syndrome”. Characteristic clinical sign of this 
syndrome is a rash in skin known as necrolytic migra-
tory erythema (NME) [8]. The glucagonoma syndrome 
is characterized by NME and diabetes mellitus (DM). 
The condition was firstly described in humans, where 
the internal lesion is most commonly a pancreatic, glu-
cagon secreting neoplasia [7]. NME is rare dermatoses 
usually seen in older animals and generally associated 
with hepatopathy or glucagonoma [3]. The disease is 
typically diagnosed in older dogs, although there are 
very rare reports of it occurring in cats [5,13,16]. Signs 
of liver disease may also be present and DM often de-
velops later in the disease process [18].
DM is a common disorder in dogs and cats, 
prevalence rate of this disease reported as ~0.4-1.2% 
[2]. Similarly in humans, the increasing frequency of 
predisposing factors such as obesity and physical in-
activity are responsible for the increasing incidence of 
diabetes in domestic cats [12,14]. Other risk factors may 
be age, neutering and gender of the animal [9]. Clini-
cal signs do not develop until hyperglycemia reaches 
a concentration that results in glycosuria, typically at 
blood glucose concentrations of 180-220 mg/dL in 
dogs and 220-270 mg/dl in cats [2]. The most common 
clinical symptoms of DM include polyphagia, polyuria, 
polydipsia, unkempt coat, muscle wasting, progressive 
weakness and loss or gain of weight [15]. The aim of this 
study was to report clinical and pathological findings of 
glucagonoma syndrome in a 12-year-old cat.
CASE
A 12-year-old female cat presented to the 
Veterinary Medical Teaching Hospital with cutaneous 
lesions of 2-month duration localized particularly at 
her neck (Figure 1a). According to the owner, she was 
healthy but in a period of 2 months lost weight and 
there was inappetite. Previously a private veterinarian 
had treated her lesions by antibiotic and antibacterial 
solution but treatment was unsuccessful. At admission, 
on physical examination, the cat was depressed but her 
body temperature, respiratory rate, heart rate were in 
normal ranges. But she had moderate dehydration and 
marked cachexia. In anamnesis owners stated frequent 
urination (polyuria) and drinking too much water 
(polydipsia) characteristic for DM.
Skin scrapes examinations were negative for 
parasites and fungi. A dermatophyte culture of hair 
was also negative. Urine and blood samples were col-
lected for analysis. Serum biochemical analysis were 
performed with Idexx Vet-Test1 equipment and reagents 
and MS9 blood counting equipment2 was used for 
hematological analysis of the blood drawn in EDTA 
tubes3. For urine analysis Idexx VetLAB UA1 equip-
ment and URIPSIN 10 urine test strips were used. The 
serum was analyzed for glucose, blood urea nitrogen 
(BUN), creatinine, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), alkaline phosphatase 
(ALP), and total protein.
For treatment Diamicron4 (30 mg, once daily), 
and a low carbohydrate, high protein diet was recom-
mended. The cat was treated with clavulanic acid with 
amoxycillin5 (Synulox Palatable Tablets) 12.5 mg/kg 
orally twice daily for her lesion in her neck. After 2 days’ 
treatment with diamicron the biochemical analysis was 
repeated (second result). The cat slowly deteriorated 
with weight loss, progressive inactivity, and a worsening 
appetite. But the neck wound was healing. Therefore, 
it was decided to use insulin. For this reason, glargine6 
recommended at 0.5 U/kg dosages [11]. After insulin 
therapy, with two days of intervals, blood analyzes 
were performed 3 times again (third, fourth and fifth 
result) [Table 1]. The lesion in the neck of the cat was 
recovering gradually. Although in the last biochemical 
analysis blood glucose value was within the reference 
levels, other parameters were high and anorexia very 
progressed. After 2 weeks the cat died and presented to 
the department of pathology for necropsy.
At necropsy, the cat was cachectic, alopecia 
and healed areas were observed on skin around the 
neck (Figure 1b). Grossly numerous whitish foci and a 
0.5x0.5 cm mass were seen at the surface of pancreas. 
Liver was enlarged and pale. Hemorrhages were ob-
served at the liver, stomach and gut. Tissue samples 
were collected and fixed in 10% buffered formalin. Af-
Figure 1. A- Gross appearance of the skin lesion of cat with in her neck at 
admission. B- Ameliorated neck lesions of the cat at necropsy.
3S. Sahinduran & O. Ozmen. 2017. Necrolytic Migratory Erythema in a Cat with Glucagonoma Syndrome.                                                            
Acta Scientiae Veterinariae. 45(Suppl 1): 223.
ter routine processing by an automatic tissue processor 
equipment (Leica ASP300S)7, tissues were embedded 
in paraffin and sectioned to 5-μm thickness by a Leica 
RM2155 rotary microtome (Leica Microsystems)7. 
Tissue sections were stained with hematoxylin-eosin 
and examined microscopically. Afterward, pancreas 
samples were immunostained with insulin antiserum 
(Anti-insulin+ Proinsulin antibody [D6C4] ab8304)8 
and glucagon antiserum (Anti glucagon antibody, 
ab8055)8 by streptavidin biotin technique. The sec-
tions were incubated with the primary antibodies for 
a period of 60 min, and immunohistochemistry was 
carried out using biotinylated secondary antibody and 
streptavidin-alkaline phosphatase conjugate. The an-
tigens were demonstrated by using diaminobenzidine 
(DAB) as the chromogen.
There were no significant changes in blood he-
matological values. Results of a urinalysis were within 
normal limits, except for glucose (1050 mg/dL at ad-
mission), and pH values (5.05 at admission). Serum 
biochemistry analysis results at admission (first results) 
and during the treatment were shown in Table 1.
At the histopathological examination of 
pancreas, loss of the histology of endocrine part was 
diagnosed. No normal Langerhans islet was seen at 
the microscopical examination and degeneration and 
fibrosis were common in exocrine part of the organ. 
Inflammatory cell infiltrations were observed at the 
pancreas. A tumoral mass surrounded by fine fibrous 
tissue was observed at the histopathological examina-
tion of the pancreas. The tumoral mass composed of 
polygonal-polyhedral neoplastic cells formed small 
packets and nests supported by thin, fibrovascular 
stroma. Neoplastic cells had round to oval nuclei that 
contained moderate amounts of stippled chromatin, 
indistinct nucleolus and abundant eosinophilic cyto-
plasm. Anisocytosis, anisokaryosis and pleomophism 
were rare (Figure 2a). Histopathological review of 
the skin revealed vacuolization at the spinous layer 
and slight inflammatory reaction. In addition, chronic 
interstitial nephritis, severe degeneration and hemor-
rhages at the liver, and hemorrhages at meningeal 
vessels were observed.
The tumoral mass had strongly positive im-
munoreaction with glucagon antibody by immuno-
histochemistry (Figure 2b). Immunohistochemical 
examination of pancreas revealed that only small 
number of insulin secretes cells characteristic for DM. 
DISCUSSION
Even in humans, glucagonomas are very rare 
tumors of endocrine pancreas. They are generally 
caused to paraneoplastic phenomena with marked le-
sions known as “glucagonoma syndrome”. The most 
prominent features of the glucagonoma syndrome are 
NME and DM. NME is generally diagnosed 70% of 
Parameter First 
results
Second 
results
Third 
results
Fourth 
results
Fifth 
results
Reference 
levels
Glucose (mg/dL) 395 340 250 175 170 70-150
BUN (mg/dL) 18 18.3 19 19.3 19.4 20-65
Creatinine (mg/dL) 4.7 4.5 4.1 4.1 3.9 0.8-2.3
AST (U/L) 345 240 190 182 180 5-55
ALT (U/L) 425 320 194 179 160 28-76
ALP (U/L) 420 350 272 265 259 0-62 
Total Protein (g/dL) 2.24 2.91 3.36 3.84 4.27 5.9-8.5
Potassium (mmol/L) 2.35 2.41 2.95 3.21 3.47 3.9-5.3
Table 1. Serum biochemical analysis results in cat before and after treatment.
Figure 2. A- Histopathology of the tumoral mass surrounded by fine fibrous 
tissue at the pancreas and polygonal tumoral cells (arrows). [HE, Bar= 100 
μm]. B- Strongly positive glucagon immunoreaction of the tumoral cells; 
Streptavidin biotin method. [Bar= 100 μm].
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patient with glucagonoma syndrome in human. NME 
is characterized with special skin rash usually occur-
ring in the glucagonoma syndrome. Glucagonoma 
syndrome is due to a slow-growing cancerous tumor 
originated from the alpha cells of the pancreas [6,19]. 
NME has been rarely reported in cats and criteria for its 
diagnosis similar by the dogs [7]. The present cat had 
characteristic clinical findings and dermatohistopathol-
ogy typical for NME. Necropsy revealed glucagonoma 
and immunohistochemistry supported the diagnosis. 
DM diagnosed by biochemical analysis of the blood 
and urine. DM supported by immunohistochemistry 
and characterized by decreased insulin secreted cells. 
Characteristic skin lesions attributed to the glucagono-
ma syndrome in this case. Although lesions generally 
localized on extremities in animal NME cases, skin 
rashes occurred on neck region in this report firstly.
The diagnosis of NME can be challenging, 
both clinically and histolopathologically. Clinically, 
the skin eruption is characterized by a pattern of spon-
taneous remissions and exacerbations. The typical 
lesions are intensely erythematous, well-demarcated 
plaques [17]. Although the exact pathogenesis of 
NME remains unclear it is thought to be due to hy-
poaminoacidemia or other nutritional deficiencies 
invoked by hyperglucagonemia [1,4]. Similar char-
acteristic clinical and pathological symptoms were 
observed in this cat. But no spontaneous remission 
was observed, amelioration on skin lesions were oc-
curred after antidiabetic treatment.
Histologically, the hallmark of NME is necro-
sis of the upper spinous layer (hence the term “necro-
lytic”) [10]. Although the characteristic histopathology 
the skin scraps were examined for mites, fungi and 
bacteria in this case. Amelioration was observed but 
marked decreased in thickness of the skin were diag-
nosed in this case after 2 weeks treatment.
The diagnosis of diabetes is based on the 
presence of appropriate clinical signs and persistent 
hyperglycemia and glycosuria. Treatment options 
are similar to those for human diabetics and include 
insulin injections (usually administered twice a day 
at 12 h intervals), dietary modifications, correction of 
obesity, exercise in dogs, and oral hypoglycemic medi-
cations in cats [2]. In this case antidiabetic treatment 
decreased the blood biochemical parameters but due to 
glucagonoma and multiple organ failure the cat died. 
The key features of the “glucagonoma syn-
drome” are NME and DM. In human NME is the most 
specific feature of the syndrome, and is the presenting 
symptom in most of the patients [6,19]. Similarly, in this 
cat, glucagonoma and DM were diagnosed as a cause of 
NME. Because of the NME is based on the secondary 
effects of glucagon, skin lesions should examine for 
endocrinopathies in cats. The diagnosis of NME might 
have a great importance, since it might be a valuable sign 
for the early detection of glucagonoma in cat.
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